Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARS1 | P26639 | 1/20 | 0.49 |
| ▸ | BMP1 | P13497 | 5/20 | 0.48 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897011 | 0.97 | BMP1 (0.52) | TARS1BMP1MMP9MMP2MMP13 | |
| SCHEMBL3898472 | 0.91 | BMP1 (0.51) | BMP1 | |
| SCHEMBL3900004 | 0.87 | BMP1 (0.55) | BMP1 | |
| SCHEMBL3911104 | 0.86 | BMP1 (0.56) | BMP1MMP9MMP2MMP14 | |
| SCHEMBL3898521 | 0.86 | BMP1 (0.51) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL3895773 | 0.82 | ALDH1A1 (0.47) | BMP1LMNA | |
| SCHEMBL3901144 | 0.82 | BMP1 (0.47) | BMP1MMP9MMP2MMP13MMP1 | |
| SCHEMBL3904165 | 0.81 | BMP1 (0.46) | BMP1LMNAHTT | |
| SCHEMBL3903242 | 0.81 | BMP1 (0.49) | BMP1 | |
| SCHEMBL3900625 | 0.81 | BMP1 (0.46) | BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | claimed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| EP-1615629-A4 | PEPTIDE DEFORMYLASE INHIBITORS | CHRISTENSEN SIEGFRIED B IV (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | claimed |
| EP-1615629-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Christensen, Siegfried B. IV (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1615629-A4 | PEPTIDE DEFORMYLASE INHIBITORS | CHRISTENSEN SIEGFRIED B IV (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | disclosed |
| EP-1615629-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Christensen, Siegfried B. IV (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229341-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | TARS1 1819/4885BMP1 1590/4885MMP9 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.